CARREEN CASTROLL: Open Payments
NPI 1639313398 · CORAM, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,366 in 104 payments from 16 companies in 2025. Trend: 2023 $3,092 · 2024 $2,614 · 2025 $2,366
Food & beverage: $2,366
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $445 |
| Neurocrine BioSciences, Inc. | 12 | $338 |
| Vanda Pharmaceuticals Inc. | 13 | $317 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $250 |
| Alkermes, Inc. | 8 | $225 |
| E.R. Squibb & Sons, L.L.C. | 6 | $172 |
| Teva Pharmaceuticals USA, Inc. | 8 | $161 |
| Axsome Therapeutics, Inc. | 5 | $111 |
| Almatica Pharma LLC | 5 | $106 |
| Bausch Health US, LLC | 3 | $57 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, ARISTADA, FANAPT, COBENFY, AUSTEDO XR, Auvelity.
Industry payments across NY — which companies pay providers there.
